Information on HR/HER2 status was not routinely available; therefore, the study population included patients with breast cancer with variable HR/HER2 status, including HR-positive breast cancer and triple-negative breast cancer (TNBC). Here, ERBB2 is linked to triple-negative breast carcinoma.